

Sig2 Labs, Inc. (the “Company”) a Delaware Corporation

Financial Statements

For the fiscal year ended December 31, 2023 and 2024

*Unaudited*

Sig2 Labs, Inc.  
Balance Sheet

Balance Sheet	Dec 31, 2024	Dec 31, 2023
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$27,623.38	\$617.33
Accounts receivable	\$0.00	\$0.00
Prepaid expenses and other assets	\$0.00	\$0.00
<b>Total current assets</b>	<b>\$27,623.38</b>	<b>\$617.33</b>
Property and equipment	\$8,671.78	\$0.00
less Accumulated Depreciation	-\$1,684.05	\$0.00
<b>Total PP&amp;E</b>	<b>\$6,987.73</b>	<b>\$0.00</b>
<b>Total assets</b>	<b>\$34,611.11</b>	<b>\$617.33</b>
<b>Liabilities and Stockholders' Equity</b>		
<b>Current liabilities:</b>		
Accounts payable	\$0.00	\$0.00
Accrued expenses	\$0.00	\$0.00
Deferred revenue and other liabilities	\$0.00	\$0.00
<b>Total current liabilities</b>	<b>\$0.00</b>	<b>\$0.00</b>
Convertible notes (non-SAFE)	\$0.00	\$0.00
Other long term liabilities	\$0.00	\$0.00
<b>Total liabilities</b>	<b>\$0.00</b>	<b>\$0.00</b>
<b>Stockholders' Equity:</b>		
Total value of common stock issued	\$0.00	\$0.00
Total value of preferred stock issued	\$0.00	\$0.00
SAFE - future equity obligation	\$242,750.00	\$0.00
Additional paid-in capital	\$10,000.00	\$4,500.00
Current-year profit/(loss)	-\$214,256.22	-\$3,882.67
Retained earnings	-\$3,882.67	\$0.00
<b>Total stockholders' equity:</b>	<b>\$34,611.11</b>	<b>\$617.33</b>
<b>Total liabilities and stockholders' equity:</b>	<b>\$34,611.11</b>	<b>\$617.33</b>

*Unaudited*

Sig2 Labs, Inc.  
Income Statement

Income Statement	Year Ended Dec. 2024	Year Ended Dec. 2023
Revenue - net	\$0.00	\$0.00
Cost of revenue	\$0.00	\$0.00
Gross profit/loss	\$0.00	\$0.00
 Selling, General & Administrative	 \$84,367.12	 \$3,295.58
Research & Development	\$128,269.27	\$731.10
Depreciation	\$1,684.05	\$0.00
Operating expenses	\$214,320.44	\$4,026.68
 Other income/expense	 \$64.22	 \$144.01
 Net profit/loss	 -\$214,256.22	 -\$3,882.67

*Unaudited*

Sig2 Labs, Inc.  
Statement of Cash Flows

<b>Statement of Cash Flows</b>	<b>Year Ended Dec, 2024</b>	<b>Year Ended Dec, 2023</b>
Cash flows from operating activities	-\$212,572.17	-\$3,882.67
Cash flows from financing activities	\$248,250.00	\$4,500.00
Cash flows from investing activities	-\$8,671.78	\$0.00
 Cash at beginning of period	 \$617.33	 \$0.00
Net increase/decrease in cash	\$27,006.05	\$617.33
Cash at the end of period	\$27,623.38	\$617.33

*Unaudited*

Sig2 Labs, Inc.  
Statement of Changes in Equity

Statement of Changes in Equity	Year Ended Dec, 2024	Year Ended Dec, 2023
Opening Balance	-\$3,882.67	\$0.00
Net profit/loss	-\$214,256.22	-\$3,882.67
Stock Issued	\$0.00	\$0.00
Preferred Stock Issued	\$0.00	\$0.00
Ending Balance	-\$218,138.89	-\$3,882.67
	\$0.00	\$0.00

*Unaudited*

Sig2 Labs, Inc.  
Notes to the Financial Statements  
For the fiscal year ended December 31, 2023 and 2024  
\$USD

## **1. ORGANIZATION AND PURPOSE**

Sig2 Labs, Inc. (the “Company”) is a corporation organized on June 22, 2023 under the laws of Delaware.

## **2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

A summary of the Company’s significant accounting policies applied in the preparation of the accompanying financial statements follows:

### **a) Basis of Accounting**

The Company prepares its financial statements on an accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America (GAAP). Under the accrual basis of accounting, revenues are recorded when earned and expenses are recorded at the time liabilities are incurred.

### **b) Use of Estimates and Assumptions**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### **c) Cash and Cash Equivalents**

Cash and cash equivalents include all cash balances, and highly liquid investments with maturities of three months or less when purchased.

### **d) Legal Fees**

Legal fees consist of legal services provided for the creation of the Company and equity financing.

### **e) Use of Estimates**

The preparation of financial statements requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

### **3. COMMITMENTS, CONTINGENCIES, COMPLIANCE WITH LAWS AND REGULATIONS**

We are currently not involved with or know of any pending or threatening litigation against the Company or any of its officers. Further, the Company is currently complying with all relevant laws and regulations.

### **4. SUBSEQUENT EVENT**

The Company has evaluated events and transactions subsequent to the period. No events require recognition in the financial statements or disclosures of the Company per the definitions and requirements of ASC Section 855-10, Subsequent Events.